Detruzitol

 Detruzitol - a drug used to improve the urodynamics
 Detruzitol - a drug to improve urodynamics.

Structure and Composition

It is produced in the form of tablets, coated tablets, in a package of 14 pieces.

One tablet contains active substance - tolterodina L-tartrate 1 mg or 2 mg.

Pharmacological action

Tolterodina L-tartrate is a specific competitive blocker of muscarinic receptors. The muscarinic receptors of the bladder has a high selectivity. Application instructions for Detruzitola reduces the frequency of urination, reduces the average amount of urination and eliminates incontinence. Active component of the drug has almost no effect on the interval QT.

Indications Detruzitola

Detruzitol according to the instructions indicated for the treatment of people suffering from urinary incontinence, frequent urination and overactive bladder.

Method of application and dosage

 Detruzitol tablets
 By Detruzitol instructions for oral administration. Tablets are swallowed whole. Take tablets with or without food. The duration of treatment depends on the severity of the disease and are individually selected by the attending physician.

Adults and elderly patients are usually prescribed by instructions Detruzitol dosage of 2 mg (in poor portability is possible to reduce the dose to 1 mg) twice a day.

Patients with reduced renal or hepatic function, as well as people receiving potent inhibitors of CYP 3A4, prescribed dosage of 1 mg tolterodina twice a day.

The recommended duration of treatment is six months. If necessary, the treatment is increased.

Side effects Detruzitola

Positive feedback on Detruzitole demonstrate its good tolerance by patients.

The most common side effects of the drug are dyspeptic symptoms, dryness of the oral mucosa and reduced tearing.

Reviews Detruzitole patients showed that adverse events are possible:

  • The sense organs and central nervous system. Perhaps the decrease in visual acuity, confusion, headache, drowsiness, disorientation in space and hallucinations, dry mucous membranes of the eyes, vertigo, memory loss, fatigue, disturbance of accommodation.
  • Gastrointestinal tract. There may be pain in the abdomen, bloating, constipation (due to decreased peristalsis), diarrhea, weight gain, gastroesophageal reflux disease, dry mucous membranes of the mouth.
  • the cardiovascular system. There tachycardia, flushing of the upper body and face.
  • Allergic reactions. You may experience allergic dermatitis, angioedema, urticaria, anaphylactic shock.

There were reviews of Detruzitole the occurrence of other side effects: urinary retention, dry skin, swelling, chest pain, pain during urination, as well as on the development of worsening symptoms of dementia.

Contraindications Detruzitola

Detruzitol of instruction is contraindicated in patients with angle-closure glaucoma is not curable, with severe ulcerative colitis, toxic megacolon, urinary retention, as well as hypersensitive to the components of the drug.

Detruzitol on instructions do not apply in pediatrics.

With care should be prescribed to patients with impaired hepatic or renal function, with the risk of urinary retention, with neytropatiey, myasthenia gravis, and reduce the risk of intestinal peristalsis.

It should be used with caution in patients Detruzitol of instructions with an elongated interval QT, being treated with antiarrhythmic drugs.

In the period of treatment should avoid driving and other potentially dangerous machinery.

Application Detruzitola during pregnancy and lactation

Tolterodin is contraindicated in pregnant and lactating women.

Interaction Detruzitola with other drugs

Reviews Detruzitole patients who combined his welcome with drugs, induces or inhibits tsitohorm P450 showed that plasma concentrations may change tolterodina. Ketoconazole, particularly in combination with tolterodinom can significantly increase its plasma concentration.

There is an increasing pharmacological action and the appearance of unwanted side effects when combined with anticholinergic drugs tolterodina.

In an application tolterodina with cisapride and metoclopramide reduced their effectiveness.

Overdose

Admission tolterodina in dosage 12, 8 mg at one time can cause painful urination and disturbance of accommodation. Reviews Detruzitole shown that in cases of overdose occur tachycardia, seizures, hallucinations, urinary retention, respiratory failure, and mydriasis.

If symptoms of overdose gastric lavage is necessary to appoint reception enterosorbents. If necessary, symptomatic therapy may be required.

In the case of anticholinergic effects such as hallucinations and over-prescribe physostigmine.

When tachycardia and respiratory violation prescribed beta-blockers and conduct artificial respiration.

In the case of seizures prescribe benzodiazepines.

With the development of mydriasis administered with pilocarpine eye drops.

When urinary retention catheterization is performed.





Яндекс.Метрика